NorwayNorway

More cash for cancer therapies

13.07.2009

Oslo – Clavis Pharma ASA, a Norwegian drug developer focused on cancer therapies, has reported that it has received EUR14m (NOK 129m) in additional funding through a private placement of 10.7 million shares led by Carnegie ASA and DnB NOR Markets as joint managers. Along with new institutional investors, the financing round was supported by existing investors, including NeoMed Management, Braganza AS and MVM Life Science Partners. “The new funds will be invested in a Phase II/III registration trial for elacytarabine in late-stage acute myeloid leukaemia,” said CEO Geir Christian Melen. Elacytarabine, a novel cytotoxic cancer drug, is one of the company’s lead candidates.
Founded in 2001, Clavis Pharma ASA is a pharmaceutical company focused on oncology that uses its proprietary Lipid Vector Technology (LVT) platform to create New Chemical Entities (NCEs) by improving already established drugs. The firm was first listed on the Oslo Stock Exchange in June 2006.
The new money will also be used to further advance other projects, including CP-4126 for the treatment in pancreatic and various solid cancers, as well as the epigenetic modulator CP-4200 for the treatment of several haematological malignancies such as MDS and leukemia.

NorwayNorway

12.05.2010

Oslo – In Norway, a discussion has begun on how to continue to support biotechnology after the current National Programme for Research in Functional Genomics in Norway (FUGE) comes to a close in 2011. Efforts to draw up a...

NorwayNorway

23.04.2010

Oslo – Norwegian cancer specialist Clavis Pharma ASA announced yesterday that its US-based development partner Clovis Oncology for CP-4126 has signed an agreement with Ventana Medical Systems, Inc. to develop a companion...

NorwayNorway

06.03.2010

Oslo/Levanger – A report released by the Research Council of Norway (RCN) proposes setting up a national biobank company in Norway. After analysing ethical, judicial and political arguments, the study ordered by the Norwegian...

NorwayNorway

01.02.2010

Cancer drug developer Clavis Pharma ASA (Oslo) has appointed Olav Hellebø as its new CEO. Hellebø, who joined Clavis Pharma from UCB at the beginning of February, is an experienced pharmaceutical executive who has held senior...

NorwayNorway

04.01.2010

Oslo – Norwegian drug delivery specialist Clavis Pharma ASA has received an unsecured loan of NOK20m (EUR2.4m) from the governmental body Innovation Norway to kick-off a Phase III registration trial with elacytarabine in 350...

NorwayNorway

22.12.2009

Oslo – Norwegian drug delivery specialist Clavis Pharma ASA has received an unsecured loan of NOK20m ($3.2m) from Innovation Norway to kick-off a phase III registration trial with elacytarabine in patients with late-stage acute...

NorwayNorway

25.11.2009

Oslo/Boulder – Norwegian drugmaker Clavis Pharma has inked a cancer drug development deal worth around US$380m with US-based Clovis Oncology, a newly formed oncology company led by former Pharmion Corporation executives. The deal...

NorwayNorway

19.09.2009

Oslo – Norway’s Algeta ASA surprised analysts with a EUR560m licensing pact for the company’s lead drug – an experimental radiotherapy that targets cancerous bone cells. Licensing partner Bayer Schering Pharma will pay US$61m in...

NorwayNorway

13.07.2009

Oslo – Prof. Harald Stenmark, head of the Centre for Cancer Biomedicine at the Norwegian Radium Hospital, has received one of the Advanced Grants distributed by the European Research Council. The oncologist will now receive...

Displaying results 21 to 30 out of 92

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-norway/browse/2/article/more-cash-for-cancer-therapies.html

Print Magazine

Product of the week

Products

Events

All Events

Current issue

All issues